Publications

• NYAG’s PFAS Suit: Litigation Defense Strategies for Consumer Product Manufacturers
  19 August 2026
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kimberly Anker
  ,
  Cara Maines
  ,
  Kaitlyn McGill
• NYAG’s PFAS Suit: Lessons for Investors
  7 August 2026
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Kimberly Anker
  ,
  Cara Maines
  ,
  Kaitlyn McGill
• Private Equity Report Fall 2025, Vol 25, No 3
  November 2025
  Christopher Anthony
  ,
  Vadim Avdeychik
  ,
  Megan K. Bannigan
  ,
  David H. Bernstein
  ,
  Tim Cornell
  ,
  Morgan A. Davis
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Uri Herzberg
  ,
  Eric T. Juergens
  ,
  Maura Kathleen Monaghan
  ,
  Gordon Moodie
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Christopher S. Ford
  ,
  Jared I. Kagan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
  ,
  Kate Saba
  ,
  Daniel N. Cohen
  ,
  Daniel Jaret
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
  ,
  Amy Pereira
• Liability Transfer Transactions: Opportunities for Funds Buying and Selling Mass Tort Exposure
  November 2025
  Morgan A. Davis
  ,
  Mark P. Goodman
  ,
  Andrew G. Jamieson
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• MarketCheck – Summer 2025
  September 2025
  Catherine Amirfar
  ,
  Andrew L. Bab
  ,
  Charu A. Chandrasekhar
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Eric T. Juergens
  ,
  Matthew E. Kaplan
  ,
  Maura Kathleen Monaghan
  ,
  Gordon Moodie
  ,
  Maeve O'Connor
  ,
  Winston M. Paes
  ,
  William D. Regner
  ,
  Paul D. Rubin
  ,
  Shannon Rose Selden
  ,
  Jane Shvets
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  William H. Taft V
  ,
  Nicholas Folly
  ,
  Caitlin Gibson
  ,
  Melissa Runsten
  ,
  Natascha Born
  ,
  Jordan Corrente Beck
  ,
  Amy Pereira
• The Food and Drug Administration Under the Second Trump Administration
  18 June 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
• New Combination Drugs: Assessing the Potential Impact of New CMS Draft Guidance on Pharmaceutical Companies and Investors
  27 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on “Most-Favored-Nation” Prescription Drug Pricing
  20 May 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Unpacking President Trump’s New Executive Order on Prescription Drug Pricing
  24 April 2025
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
  ,
  Adriana Kranjac Rielly
• Top 10 Healthcare and Life Sciences Issues to Watch in 2025
  10 January 2025
  Andrew L. Bab
  ,
  Tim Cornell
  ,
  Avi Gesser
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Erez Liebermann
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Jane Shvets
  ,
  Patrick Taylor
  ,
  Erica S. Weisgerber
  ,
  Carter Burwell
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Lillian Lara
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Kaitlyn McGill
  ,
  Adam C. Saunders
  ,
  Mackenzie Mendolla
• 2024 Private Equity Midyear Outlook
  August 2024
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Christopher Dortschy
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Morgan J. Hayes
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Arian M. June
  ,
  Robert B. Kaplan
  ,
  M. Natasha Labovitz
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Gregory J. Lyons
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Sheena Paul
  ,
  Marc Ponchione
  ,
  Ryan T. Rafferty
  ,
  Julie M. Riewe
  ,
  Paul D. Rubin
  ,
  Scott B. Selinger
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  Rick Sofield
  ,
  Katherine Durnan Taylor
  ,
  Ramya S. Tiller
  ,
  Jonathan R. Tuttle
  ,
  Patricia Volhard
  ,
  Erica S. Weisgerber
  ,
  Jennifer Wheater
  ,
  Naomi Aoyama
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Jennifer R. Cestaro
  ,
  Robert T. Dura
  ,
  Paul Eastham
  ,
  Stuart Hammer
  ,
  Lauren P. Heller
  ,
  Jin-Hyuk Jang
  ,
  Wen-Wei Lai
  ,
  Melissa Runsten
  ,
  Tricia Bozyk Sherno
  ,
  Jacob W. Stahl
  ,
  John Young
  ,
  Ulysses Smith
  ,
  Kayleigh Anderson
  ,
  Hymie A. Anteby
  ,
  Jabari Benjamin
  ,
  Josephine Chen
  ,
  Jordan Corrente Beck
  ,
  Julia Needle
  ,
  Michael C. Godbe
  ,
  Zoe Jacoby
  ,
  Yiran Ji
  ,
  Adriana Kranjac Rielly
  ,
  Paul D. Lowry
  ,
  Kaitlyn McGill
  ,
  Amy Pereira
  ,
  Eike Björn Weidner
  ,
  Keith Moshe
• Increased FCA Enforcement Targeting PE Firms Expected in 2024
  11 March 2024
  Helen V. Cantwell
  ,
  Courtney M. Dankworth
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Shannon Rose Selden
  ,
  Jacob W. Stahl
  ,
  Kaitlyn McGill
• Chevron Under Fire: What Healthcare and Life Sciences Investors Should Know
  19 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Zoe Jacoby
  ,
  Adriana Kranjac Rielly
  ,
  Kaitlyn McGill
• Top 10 Healthcare and Life Sciences Issues to Watch in 2024
  4 January 2024
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Melissa Runsten
  ,
  Jacob W. Stahl
  ,
  Ilya Balabanovsky
  ,
  Margaret Howard
  ,
  James Lapp
  ,
  Hannah R. Levine
  ,
  Zoe Jacoby
  ,
  Kaitlyn McGill
• CMS Announces First Ten Medicare Part D Drugs Subject to Price Negotiations
  6 October 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• 2023 Private Equity Midyear Outlook
  27 July 2023
  Christopher Anthony
  ,
  Katherine Ashton
  ,
  Dominic Blaxill
  ,
  Ezra Borut
  ,
  Geoffrey P. Burgess
  ,
  Andrew J. Ceresney
  ,
  Jeffrey P. Cunard
  ,
  E. Drew Dutton
  ,
  Jane Engelhardt
  ,
  Andrew Ford
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Ted Hassi
  ,
  Morgan J. Hayes
  ,
  Emily F. Huang
  ,
  Peter J. Irwin
  ,
  Eric T. Juergens
  ,
  Robert B. Kaplan
  ,
  Rafael Kariyev
  ,
  M. Natasha Labovitz
  ,
  Maurizio Levi-Minzi
  ,
  Andrew M. Levine
  ,
  Sidney P. Levinson
  ,
  Jonathan F. Lewis
  ,
  Timothy McIver
  ,
  Frank Mitchell
  ,
  Maura Kathleen Monaghan
  ,
  Edwin Northover
  ,
  Brett M. Novick
  ,
  Marc Ponchione
  ,
  Julie M. Riewe
  ,
  Shannon Rose Selden
  ,
  Steven J. Slutzky
  ,
  Thomas Smith
  ,
  Kristin A. Snyder
  ,
  J. Michael Snypes, Jr.
  ,
  Patrick Taylor
  ,
  Ramya S. Tiller
  ,
  Patricia Volhard
  ,
  Richard Ward
  ,
  Erica S. Weisgerber
  ,
  Alison E. Buckley-Serfass
  ,
  Brett Adam Bush
  ,
  Robert T. Dura
  ,
  Stuart Hammer
  ,
  Sheena Paul
  ,
  Tricia Bozyk Sherno
  ,
  Ulysses Smith
  ,
  Jacob W. Stahl
  ,
  Sergio Torres
  ,
  Jennifer Wheater
  ,
  Elie J. Worenklein
  ,
  Colleen B. Bernaiche
  ,
  Paul Eastham
  ,
  Christopher Gossage
  ,
  Yiran Ji
  ,
  Maryam Kanna
  ,
  Rekha Korlipara Kreider
  ,
  Adriana Kranjac Rielly
  ,
  Samuel D. Krawiecz
  ,
  Megan MacDonald
  ,
  Harshil Mehta
  ,
  Stanley G. Seckler
  ,
  Sheng Shao
  ,
  Massy Vainshtein
  ,
  Kimberly Anker
• Law360: DOJ Actions Signal Rising Enforcement Risk For Health Cos.
  14 July 2023
  Law360
  Nicholas Folly
  ,
  Jane Shvets
  ,
  Maura Kathleen Monaghan
  ,
  Winston M. Paes
  ,
  Douglas S. Zolkind
  ,
  David A. O'Neil
  ,
  Mark P. Goodman
  ,
  Erich O. Grosz
  ,
  Andrew M. Levine
• New York Seeks Review and Approval Authority over Certain Healthcare Transactions
  7 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Proceed with Caution: Online Tracking Technologies Pose HIPAA Compliance Risks
  2 March 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Hannah R. Levine
• Top 15 Healthcare and Life Sciences Issues to Watch in 2023
  9 January 2023
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Jacob W. Stahl
  ,
  Elie J. Worenklein
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
  ,
  Adam C. Saunders
  ,
  Micah A. Rubin
• Implications of the Inflation Reduction Act for Investors in Life Sciences Companies
  November 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Private Equity Report Fall 2022, Vol 22, No 3
  November 2022
  Andrew L. Bab
  ,
  Sally Bergmann Hardesty
  ,
  Michael Bolotin
  ,
  Erin Cleary
  ,
  Matthew Dickman
  ,
  Gregory V. Gooding
  ,
  Mark P. Goodman
  ,
  Mark Johnson
  ,
  Henry Lebowitz
  ,
  Maurizio Levi-Minzi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Kevin M. Schmidt
  ,
  Scott B. Selinger
  ,
  Ramya S. Tiller
  ,
  Jin-Hyuk Jang
  ,
  Hannah R. Levine
  ,
  Keith J. Slattery
  ,
  Sergio Torres
  ,
  Dominique Trudelle
  ,
  Hadel Alfagir
  ,
  David N. Simpser
• New York’s Adult Survivors Act to Take Effect on November 24, 2022
  22 November 2022
  Helen V. Cantwell
  ,
  Mark P. Goodman
  ,
  Jyotin Hamid
  ,
  Mary Beth Hogan
  ,
  Arian M. June
  ,
  Tricia Bozyk Sherno
• Dealmaking Implications of California’s New Healthcare Cost Monitoring Law
  19 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Recent SCOTUS Decisions Impacting Healthcare
  3 August 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• FTC Sharpens Focus on Private Equity
  17 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Ted Hassi
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Michael Schaper
  ,
  Erica S. Weisgerber
  ,
  Adam C. Saunders
• California Poised to Grant Attorney General Broad Approval Authority over Healthcare Transactions
  16 June 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
• Texas Federal Judge Sides with Providers in “No Surprises Act” Ruling
  1 March 2022
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Adriana Kranjac Rielly
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• The Supreme Court TransUnion Case: Part 2—What It Means for Efforts to Defeat Class Certification?
  9 July 2021
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jim Pastore
  ,
  Jacob W. Stahl
• The American Rescue Plan Act of 2021: Implications for Healthcare and Life Sciences Companies
  12 March 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Hannah R. Levine
  ,
  Melissa Runsten
• Proposed Elimination of Medicaid Rebate Cap Could Negatively Impact Innovator Pharmaceutical Industry
  11 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Biden Takes Aim at Trump Administration Healthcare Policies
  2 February 2021
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Consolidated Appropriations Act: Implications for Healthcare and Life Sciences Companies
  30 December 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Trump Administration’s Final Drug Pricing Hurrah—Will It Last?
  24 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19 Vaccines: FDA Regulatory Timeline and Next Steps Prior to Widespread Distribution
  20 November 2020
  Paul D. Rubin
  ,
  Melissa Runsten
  ,
  Kevin Rinker
  ,
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Federal Government Shines Spotlight on Speaker Programs
  20 November 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• The Potential Impact of a Biden Administration on Life Sciences, Healthcare, and Consumer Product Companies and Investors
  2 November 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Maura Kathleen Monaghan
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Trump’s Newest Drug Pricing Executive Order: Still Much More Bark than Bite
  16 September 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Senate Subcommittee Report Highlights Money Laundering and Sanctions Risks in the Art Industry
  27 August 2020
  Mark P. Goodman
  ,
  Satish M. Kini
  ,
  Andrew M. Levine
  ,
  William H. Taft V
• HHS Announces Additional CARES Act Funding for Qualifying Providers
  4 August 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Trump’s New Drug Pricing Executive Orders: Much More Bark Than Bite
  29 July 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• HHS Issues Additional Guidance on Qualifications for CARES Act Funding
  8 May 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Appropriations for Healthcare Providers Related to COVID-19
  30 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• New Appropriation for Healthcare Providers
  24 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Announces Additional Funding for Healthcare Providers Impacted by COVID-19
  23 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• HHS Distributing $30 Billion in Grants to Medicare Providers
  10 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CMS Announces Intent to Provide $30 Billion to Medicare Providers
  9 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Update Regarding Public Health and Social Services Emergency Fund
  6 April 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
• The Federal Government Throws a Lifeline to Medicare Providers and Suppliers
  30 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• CARES Act: Implications for Healthcare and Life Science Companies and Investors
  27 March 2020
  Andrew L. Bab
  ,
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: CMS Expands Medicare Coverage for Telehealth Services amid Public Health Emergency
  20 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• COVID-19: FDA Developments and Legal Considerations for Healthcare and Life Science Companies and Investors
  17 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl
  ,
  Melissa Runsten
• Ninth Circuit Decision Increases Risk of RICO Economic Loss Claims Against Pharmaceutical Manufacturers and Highlights Evolving Circuit Split
  6 March 2020
  Mark P. Goodman
  ,
  Maura Kathleen Monaghan
  ,
  J. Robert Abraham
• Law360: How Tax Reform Could Impact the Health Care Industry
  15 November 2017
  Andrew L. Bab
  ,
  Peter A. Furci
  ,
  Mark P. Goodman
  ,
  Kevin Rinker
  ,
  Paul D. Rubin
  ,
  Jacob W. Stahl